Zabadinostat is under clinical development by IngenOx Therapeutics and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData, Phase II drugs for Hepatocellular Carcinoma have a 33% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Zabadinostat’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Zabadinostat overview
Zabadinostat is under development for the treatment of solid tumors including colorectal cancer and haematological cancers including peripheral T-cell lymphomas and hepatocellular carcinoma. The drug candidate acts by targeting enzyme histone deacetylase (HDAC). The drug candidate is administered by oral route. It is developed in conjunction with its proprietary CancerNav predictive biomarker platform. It was also under development for lung, cervical, breast, primary mediastinal b-cell lymphoma, pancreatic, ovarian and ENT cancer and haematological cancers including Hodgkin lymphoma, angioimmunoblastic T-cell lymphoma (AITL), multiple myeloma, follicular lymphoma, Gray Zone non-Hodgkin lymphoma and Waldenstrom macroglobulinemia (lymphoplasmacytic lymphoma), diffuse large B-cell lymphoma.
IngenOx Therapeutics overview
IngenOx Therapeutics a clinical-stage company which focuses on developing innovative drugs and vaccines aimed at re-invigorating the immune response against cold tumours. The company is headquartered in Oxford, England, the UK.
For a complete picture of Zabadinostat’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
